1. Home
  2. ORIO vs CLRB Comparison

ORIO vs CLRB Comparison

Compare ORIO & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Orion Digital Corp. Common Shares

ORIO

Orion Digital Corp. Common Shares

N/A

Current Price

$1.06

Market Cap

20.5M

Sector

N/A

ML Signal

N/A

Logo Cellectar Biosciences Inc.

CLRB

Cellectar Biosciences Inc.

N/A

Current Price

$1.24

Market Cap

24.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ORIO
CLRB
Founded
N/A
2002
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.5M
24.5M
IPO Year
2014
2008

Fundamental Metrics

Financial Performance
Metric
ORIO
CLRB
Price
$1.06
$1.24
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $11.50
AVG Volume (30 Days)
111.3K
★ 150.4K
Earning Date
11-05-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$64.78
N/A
Revenue Next Year
$7.46
N/A
P/E Ratio
$4.93
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$1.11
52 Week High
$1.40
$4.70

Technical Indicators

Market Signals
Indicator
ORIO
CLRB
Relative Strength Index (RSI) 60.88 40.03
Support Level $1.02 N/A
Resistance Level $1.13 $1.37
Average True Range (ATR) 0.08 0.09
MACD 0.02 0.04
Stochastic Oscillator 70.79 46.15

Price Performance

Historical Comparison
ORIO
CLRB

About ORIO Orion Digital Corp. Common Shares

Orion Digital Corp is a financial technology company operating digital platforms across wealth and payments, supported by a consumer lending business in Canada. The Company's Wealth platform, Intelligent Investing, provides long-term investment solutions to the Canadian market. It also operates a consumer lending business in Canada. Its Payments business is conducted through its wholly owned subsidiary, which provides issuer processing, program management, and regulated payment orchestration services across Europe. The Company operates in Canada and Europe, with Canada generating the majority of its revenue.

About CLRB Cellectar Biosciences Inc.

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.

Share on Social Networks: